The Impact of iStent trabecular micro-bypass implantation on patients' quality of life

Thème:
Glaucome
Quoi:
Paper Presentation | Présentation d'article
Quand:
4:05 PM, dimanche 27 juin 2021 (5 minutes)
Discussion:
0

Authors: John Liu, William McCollum, Martharoot N. Malungu, Iqbal K. Ahmed. University of Toronto.

Author Disclosure Block:J. Liu: None. W. McCollum: None. M.N. Malungu: None. I.K. Ahmed: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Alcon, Allergan, Carl Zeiss Meditec, Johnson & Johnson Vision, MST Surgical, Mundipharma. Any direct financial payments including receipt of honoraria; Description of relationship(s); Speakers Honoraria. Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Alcon, Allergan, Camras Vision, Glaukos, Ivantis, Johnson & Johnson Vision, New World Medical, Santen. Funded grants or clinical trials; Description of relationship(s); Research Grants/Support. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Name of for-profit or not-for-profit organization(s); Aequus, Aerie Pharmaceuticals, Akorn. Allergan, ArcScan, Bausch Health, Beaver Visitec, Beyeonics, Camras Vision, Carl Zeiss Meditec, CorNeat Vision, Ellex, ELT Sight, ElutiMed, Equinox, Genentech, Gl. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity; Description of relationship(s); Consulting.

Abstract Title:The Impact of iStent Trabecular Micro-Bypass Implantation on Patients' Quality of Life

Abstract Body:

Purpose: To describe the reported quality of life (QOL) in patients 1 month after iStent implantation via validated QOL questionnaires.
Study Design: This is a prospective cohort study.
Methods: QOL data was be obtained from all patients receiving iStent Trabecular Micro-Bypass Implantation by providing them with validated QOL questionnaires both pre-operatively and 1-month post-operatively. The questionnaires include the following: the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), which has 12 domains (general health, general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, colour vision, and peripheral vision), the Glaucoma Symptom Health Problem Chart (SHPC-18), which has 2 sections (local eye symptoms and visual function problems), and the 36-Item Short Form Survey (SF-36), which has 8 domains (physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, general health). All pre-operative and post-operative surveys were compared using Wilcoxon Signed-Rank Test with significance determined at p<0.05.
Results: A total of 51 participants received iStent Trabecular Micro-Bypass and were enrolled in the study and 47 participants completed both pre-operative and post-operative questionnaires. On NEI-VFQ-25, there was no significant difference between average pre-operative and post-operative QOL scores for general health; however, significant differences were found in the other 11 domains (p<0.05), which were all reported to have a significantly higher post-operative QOL. On SHPC-18, average scores for QOL in both categories (local eye symptoms and visual function problems) were significantly higher post-operatively (p<0.01). On SF-36, there were no significant differences found between pre-operative and post-operative average QOL measures for role limitations due to physical health, role limitations due to emotional problems, emotional well-being, social functioning, pain, and general health. However, significant differences were found for physical functioning (p<0.01), energy/fatigue (p=0.02), and in overall composite score (p<0.01), which were shown to be significant for a higher QOL post-operatively.
Conclusions: Concern over patients’ quality of life after surgical treatments has grown over the years. Our results show there is no measurable decrease in quality of life in patients 1 month post-operatively after iStent Trabecular Micro-Bypass implantation surgery. As the iStent is a minimally invasive glaucoma surgery (MIGS), it is known to have a lower complication rate and more predictable post-operative course, and thus may prevent or reduce a decrease in quality of life. Future comparisons with other glaucoma surgeries or longer-term data could be considered to better characterize patients’ quality of life after MIGS.